Pub Date : 2023-10-22DOI: 10.33004/reumatizam-69-2-7
{"title":"Prof. Theodor Dürrigl, MD, PhD (10th September 1926 – 20th July 2022)","authors":"","doi":"10.33004/reumatizam-69-2-7","DOIUrl":"https://doi.org/10.33004/reumatizam-69-2-7","url":null,"abstract":"","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135462449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-22DOI: 10.33004/reumatizam-69-2-2
{"title":"Clinical presentation and treatment of adult-onset Still disease – a single-centre experience","authors":"","doi":"10.33004/reumatizam-69-2-2","DOIUrl":"https://doi.org/10.33004/reumatizam-69-2-2","url":null,"abstract":"","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":"23 1-2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135462109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-28DOI: 10.33004/reumatizam-69-1-2
M. Šestan, Danica Grguric, N. Kifer, Ante vidović, M. Frković, M. Jelušić
Introduction: iga vasculitis (igav) is the most common systemic vasculitis in childhood. Purpuric rash is a man-datory criterion for diagnosing igav, it is mostly localized on the lower extremities and gluteal region, although it can also appear atypically affecting the face, trunk and upper extremities. in the most severe cases, ulcerations, necrosis and bullae can be present. Objectives: to evaluate the characteristics of cutaneous manifestations in patients with igav and to examine its association with clinical features. Subjects and methods: Retrospective analysis of data from patients with igav diagnosed and treated at the Referral centre for Paediatric and adolescent Rheumatology of the ministry of health of the Republic of croatia, in the period from january 2009 to December 2021. Results: igav was diagnosed in 234 patients, 124 boys and 110 girls with the median (range) age at the time of diagnosis of 6.5 (4.5–8.2) years. all patients had a purpuric rash, and in 127 of them (54.3%) igav began with a rash. cutaneous manifestations were most often presented in the form of palpable purpura and/or petechiae (87.2%) and in all patients were localized on the lower extremities. in 103 patients (44%) purpuric rash spread further to the upper extremities, trunk and/or face. at least one skin relapse occurred in 47 patients (20.1%). The most severe cutaneous manifestations which included ulcerations and necrosis developed in 11 patients (4.7%). Patients with cutaneous manifestations spread above the waist had a more statistically significant gastrointestinal involvement compared to patients with cutaneous manifestations affecting the lower extremities and gluteal region (50.5% vs. 36.6%, p=0.033), higher incidence of iga vasculitis nephritis (igavn) (31.1% vs. 19.8%, p=0.048) and were more frequently treated with systemic glucocorticoids (68% vs. 52.7%, p=0.018) and angiotensin-converting enzyme inhibitors (14.5% vs. 5.3%, p=0.016). almost all patients with ulcerations and necrosis required treatment with systemic glucocorticoids compared to the rest (90.9% vs. 57.8%,p=0.031). Conclusion: We observed that patients with purpuric rash spread above the waist have more frequently affected gastrointestinal system and a higher incidence of igavn. The prevalence of ulcerations and necrosis in igav is less common than the standard purpuric rash and this group of patients required systemic glucocorticoid therapy.
{"title":"Association between cutaneous manifestations and clinical features of IgA vasculitis","authors":"M. Šestan, Danica Grguric, N. Kifer, Ante vidović, M. Frković, M. Jelušić","doi":"10.33004/reumatizam-69-1-2","DOIUrl":"https://doi.org/10.33004/reumatizam-69-1-2","url":null,"abstract":"Introduction: iga vasculitis (igav) is the most common systemic vasculitis in childhood. Purpuric rash is a man-datory criterion for diagnosing igav, it is mostly localized on the lower extremities and gluteal region, although it can also appear atypically affecting the face, trunk and upper extremities. in the most severe cases, ulcerations, necrosis and bullae can be present. Objectives: to evaluate the characteristics of cutaneous manifestations in patients with igav and to examine its association with clinical features. Subjects and methods: Retrospective analysis of data from patients with igav diagnosed and treated at the Referral centre for Paediatric and adolescent Rheumatology of the ministry of health of the Republic of croatia, in the period from january 2009 to December 2021. Results: igav was diagnosed in 234 patients, 124 boys and 110 girls with the median (range) age at the time of diagnosis of 6.5 (4.5–8.2) years. all patients had a purpuric rash, and in 127 of them (54.3%) igav began with a rash. cutaneous manifestations were most often presented in the form of palpable purpura and/or petechiae (87.2%) and in all patients were localized on the lower extremities. in 103 patients (44%) purpuric rash spread further to the upper extremities, trunk and/or face. at least one skin relapse occurred in 47 patients (20.1%). The most severe cutaneous manifestations which included ulcerations and necrosis developed in 11 patients (4.7%). Patients with cutaneous manifestations spread above the waist had a more statistically significant gastrointestinal involvement compared to patients with cutaneous manifestations affecting the lower extremities and gluteal region (50.5% vs. 36.6%, p=0.033), higher incidence of iga vasculitis nephritis (igavn) (31.1% vs. 19.8%, p=0.048) and were more frequently treated with systemic glucocorticoids (68% vs. 52.7%, p=0.018) and angiotensin-converting enzyme inhibitors (14.5% vs. 5.3%, p=0.016). almost all patients with ulcerations and necrosis required treatment with systemic glucocorticoids compared to the rest (90.9% vs. 57.8%,p=0.031). Conclusion: We observed that patients with purpuric rash spread above the waist have more frequently affected gastrointestinal system and a higher incidence of igavn. The prevalence of ulcerations and necrosis in igav is less common than the standard purpuric rash and this group of patients required systemic glucocorticoid therapy.","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47395740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-28DOI: 10.33004/reumatizam-69-1-4
Stipe Ćavar, F. Grubišić, H. S. Kavanagh, Ines Doko Vajdić, S. Grazio
The aim of this study was to investigate the course and outcome of COVID in patients with inflammatory rheumatic diseases (IRD) who are on biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). In this study, we used the data of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who had been treated at the Department of Rheumatology, Physical and Rehabilitation Medicine of the Sestre milosrdnice University Hospital in Zagreb (Croatia) and in whose case the SARS-CoV-2 infection was proven in the period from February 2020 until the end of July 2021. In order to analyse this data, we have used the methods of descriptive statistics. Out of a total of 28 patients, 6 had a severe or critical case of COVID-19, but only one subject was hospitalized. All 6 patients were treated with bDMARDs before the onset of infection. Most of them (4/6) had moderate to high disease activity of IRD, as well as multiple comorbidities. No deaths were recorded in this cohort of patients. The results of this study suggest that the course of COVID-19 is associated with the disease activity of IRD and accompanying comorbidities, whereas the use of specific biological drugs might be associated with a more favourable outcome of the infection. Therefore, a better follow-up process and management of disease activity in patients with IRD should be implemented during the period of this pandemic, as well as the modification of specific therapy.
{"title":"COVID-19 COURSE AND OUTCOME IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES WHO ARE ON BIOLOGICAL OR TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS – RESULTS FROM A SINGLE RHEUMATOLOGY CENTRE","authors":"Stipe Ćavar, F. Grubišić, H. S. Kavanagh, Ines Doko Vajdić, S. Grazio","doi":"10.33004/reumatizam-69-1-4","DOIUrl":"https://doi.org/10.33004/reumatizam-69-1-4","url":null,"abstract":"The aim of this study was to investigate the course and outcome of COVID in patients with inflammatory rheumatic diseases (IRD) who are on biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). In this study, we used the data of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who had been treated at the Department of Rheumatology, Physical and Rehabilitation Medicine of the Sestre milosrdnice University Hospital in Zagreb (Croatia) and in whose case the SARS-CoV-2 infection was proven in the period from February 2020 until the end of July 2021. In order to analyse this data, we have used the methods of descriptive statistics. Out of a total of 28 patients, 6 had a severe or critical case of COVID-19, but only one subject was hospitalized. All 6 patients were treated with bDMARDs before the onset of infection. Most of them (4/6) had moderate to high disease activity of IRD, as well as multiple comorbidities. No deaths were recorded in this cohort of patients. The results of this study suggest that the course of COVID-19 is associated with the disease activity of IRD and accompanying comorbidities, whereas the use of specific biological drugs might be associated with a more favourable outcome of the infection. Therefore, a better follow-up process and management of disease activity in patients with IRD should be implemented during the period of this pandemic, as well as the modification of specific therapy.","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47550165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-28DOI: 10.33004/reumatizam-69-1-1
{"title":"Gender differences in patients with Sjögren’s syndrome: A 10-year single centre experience","authors":"","doi":"10.33004/reumatizam-69-1-1","DOIUrl":"https://doi.org/10.33004/reumatizam-69-1-1","url":null,"abstract":"","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43102148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-28DOI: 10.33004/reumatizam-69-1-5
{"title":"Diagnosis and classification criteria of Sjögren’s syndrome","authors":"","doi":"10.33004/reumatizam-69-1-5","DOIUrl":"https://doi.org/10.33004/reumatizam-69-1-5","url":null,"abstract":"","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43044075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-28DOI: 10.33004/reumatizam-69-1-6
Martina Jambrović, M. Cerovec, I. Padjen, B. Anić
inflammatory rheumatic diseases are chronic, progressive autoimmune diseases which affect the musculoskeletal system and other organ systems. nowadays, a large number of patients is treated with biological therapy. although biological drugs selectively affect specific molecules of the immune system, they weaken the overall immune system of the body. Therefore, the patients are more susceptible to infections and other diseases such as lymphomas, breast and skin cancers and melanomas. Chronic inflammation which occurs due to autoimmune disease is also a risk factor for malignant development. so far, studies have not proven direct correlation between biological therapy and solid or haematologic tumours. on the other hand, the increased risk for developing skin cancer in patients on tumour necrosis factor alpha inhibitors has been described. in this review paper we analysed the available medical literature on the risks for malignant disease development in patients with rheumatic diseases who are on biological disease – modifying anti-rheumatic drugs.
{"title":"Association of biological therapy and malignancy in inflammatory rheumatic diseases","authors":"Martina Jambrović, M. Cerovec, I. Padjen, B. Anić","doi":"10.33004/reumatizam-69-1-6","DOIUrl":"https://doi.org/10.33004/reumatizam-69-1-6","url":null,"abstract":"inflammatory rheumatic diseases are chronic, progressive autoimmune diseases which affect the musculoskeletal system and other organ systems. nowadays, a large number of patients is treated with biological therapy. although biological drugs selectively affect specific molecules of the immune system, they weaken the overall immune system of the body. Therefore, the patients are more susceptible to infections and other diseases such as lymphomas, breast and skin cancers and melanomas. Chronic inflammation which occurs due to autoimmune disease is also a risk factor for malignant development. so far, studies have not proven direct correlation between biological therapy and solid or haematologic tumours. on the other hand, the increased risk for developing skin cancer in patients on tumour necrosis factor alpha inhibitors has been described. in this review paper we analysed the available medical literature on the risks for malignant disease development in patients with rheumatic diseases who are on biological disease – modifying anti-rheumatic drugs.","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44649440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-28DOI: 10.33004/reumatizam-69-1-3
ana Šimac, Željka Kardum, Jasmin Ahić, Ana Marija Masle, K. K. stranski, V. Prus
Objectives: vasculitis is a rare disease characterized by inflammation and necrosis of blood vessels. inflammation-induced thrombosis is a hallmark of several autoimmune diseases, such as systemic lupus erythematosus (sle), rheumatoid arthritis (ra), sjögren’s syndrome (ss)
{"title":"Incidence of thromboembolic events in patients with a systemic form of vasculitis and cutaneous vasculitis","authors":"ana Šimac, Željka Kardum, Jasmin Ahić, Ana Marija Masle, K. K. stranski, V. Prus","doi":"10.33004/reumatizam-69-1-3","DOIUrl":"https://doi.org/10.33004/reumatizam-69-1-3","url":null,"abstract":"Objectives: vasculitis is a rare disease characterized by inflammation and necrosis of blood vessels. inflammation-induced thrombosis is a hallmark of several autoimmune diseases, such as systemic lupus erythematosus (sle), rheumatoid arthritis (ra), sjögren’s syndrome (ss)","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48958565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-05DOI: 10.33004/reumatizam-68-2-5
{"title":"THERAPEUTIC APPROACH TO A PATIENT WITH ANTISYNTHETASE SYNDROME – A CASE REPORT","authors":"","doi":"10.33004/reumatizam-68-2-5","DOIUrl":"https://doi.org/10.33004/reumatizam-68-2-5","url":null,"abstract":"","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46225963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-05DOI: 10.33004/reumatizam-68-2-3
sjögren’s syndrome (ss) is a chronic autoimmune disease in which chronic lymphocytic infiltration leads to progressive destruction of the exocrine glands and consequently causes the dry syndrome. The most commonly affected are the lacrimal and salivary glands. less often, ss presents with the symptoms of exocrine glands of other localisation, arthritis, myositis, vasculitis involving the skin and the nervous system, interstitial lung disease
{"title":"Indolent extranodal B-NHL CD20 positive MALT lymphoma in a patient with primary Sjögren’s syndrome with a good response to rituximab treatment","authors":"","doi":"10.33004/reumatizam-68-2-3","DOIUrl":"https://doi.org/10.33004/reumatizam-68-2-3","url":null,"abstract":"sjögren’s syndrome (ss) is a chronic autoimmune disease in which chronic lymphocytic infiltration leads to progressive destruction of the exocrine glands and consequently causes the dry syndrome. The most commonly affected are the lacrimal and salivary glands. less often, ss presents with the symptoms of exocrine glands of other localisation, arthritis, myositis, vasculitis involving the skin and the nervous system, interstitial lung disease","PeriodicalId":76426,"journal":{"name":"Reumatizam","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48898638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：